Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Resonance Health Sparks Interest
Dec 05 2016
Resonance Health has captured the imagination of NDF Research with its world-leading MRI diagnostics, resulting in an initiation of coverage.
Patent Dispute Hinders Fisher & Paykel Healthcare
Nov 24 2016
Fisher & Paykel Healthcare has signalled robust growth in its hospital applications but remains hindered by a patent dispute with ResMed.
Treasure Chest: CSL’s Heart Data Under Microscope
Nov 15 2016
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Ahead of the release of important data on CSL’s heart disease product, brokers acknowledge potentially substantial upside.
Healthscope To Be Avoided
Oct 25 2016
Michael Gable of Fairmont Equities suggests there may yet be further downside to come for Healthscope.
CORR: Healthscope Rattles Market But Brokers Less Anxious
Oct 24 2016
Healthscope has rattled the market, announcing a very weak September quarter and flagging the prospect of a flat revenue outcome in FY17 if the trend continues.
Treasure Chest: Pro Medicus Opportunity Immense
Oct 20 2016
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Moelis upgrades medical imaging software company Pro Medicus to Buy, citing an extensive growth opportunity in the US.
AdAlta Advances With Pulmonary Fibrosis Treatment
Sep 14 2016
AdAlta, a Melbourne-based drug developer, recently listed on ASX and NDF Research takes up coverage of the stock.
Sigma Pharma’s Expansion Strategy On Track
Sep 12 2016
Sigma Pharmaceuticals is expanding its reach into hospital pharmacy while maintaining a stable base business. Brokers welcome the increased diversity.
Is Cochlear Overvalued?
Aug 10 2016
Cochlear has taken advantage of sales growth to reinvest in development. While brokers approve, they question whether the stock’s current premium is justified.
Just Cough Into Your Phone
Jul 26 2016
Recently listed ResApp Health has developed a digital system that could revolutionise the diagnosis of respiratory disorders.
